Therefore, C9 and CsA may more potently suppress the growth of EGFR-mutant NSCLC CSCs with higher EGFR dependence than EGFR-wild-type NSCLC CSCs by targeting the CypA/CD147 axis. The gene discussed is BSG; the disease is non-small cell lung carcinoma.